Mark Phillip Hogarth

Title: Mark Phillip Hogarth: Innovator in Fc Receptor Modulation

Introduction

Mark Phillip Hogarth is a distinguished inventor based in Williamstown, Australia. He has made significant contributions to the field of biomedical research, particularly in the development of compounds that modulate Fc receptor activity. With a total of 2 patents to his name, Hogarth's work is paving the way for new treatments in autoimmune diseases.

Latest Patents

Hogarth's latest patents focus on Fc receptor modulating compounds and compositions. The inventions provide compounds capable of binding to an Fc receptor and modulating its activity. These compounds feature a core lipophilic group in the form of an Aryl ring, which is substituted with a group rich in p-electrons. The patents also describe methods for treating autoimmune diseases that involve Fc receptor activity using these compounds. Additionally, a method for obtaining such compounds is outlined, which includes designing compounds with specific structural characteristics to fit in the groove of the FcγRIIa structure and screening them for modulating activity on the Fc receptor.

Career Highlights

Hogarth is currently associated with Trillium Therapeutics Inc., where he continues to innovate in the field of therapeutic compounds. His work has garnered attention for its potential impact on treating complex autoimmune conditions.

Collaborations

Throughout his career, Hogarth has collaborated with notable colleagues, including Geoffrey Allan Pietersz and Gerard Peter Moloney. These collaborations have further enriched his research and development efforts.

Conclusion

Mark Phillip Hogarth is a prominent figure in the field of Fc receptor modulation, with a focus on developing innovative treatments for autoimmune diseases. His contributions through patents and collaborations highlight his commitment to advancing biomedical research.